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Abstract
Background: Stigma and discrimination may adversely affect the benefits of methadone maintenance treatment
(MMT) for drug users, especially in disadvantaged settings. This study assessed stigma and discrimination against
MMT patients in the mountainous and rural areas in Vietnam and explored their associated factors to inform
implementation strategies.
Methods: We interviewed 241 MMT patients in two clinics: one in Tuyen Quang Province’s inner city and the other
in Son Duong District, to assess stigma and discrimination that patients perceived and experienced. Socioeconomic
status, health behaviors, health status, and history of drug abuse were examined. Multivariate linear and logistic
regression models were used to explore factors associated with stigma and discrimination.
Results: The majority of respondents reported experiencing stigma and discrimination including blame/judgment (95.1%),
shame (95.1%), disclosure (71.4%), and the fear of human immunodeficiency virus (HIV) transmission by others (74.1%).
Unemployed patients were more likely to experience discrimination (Coef =−1.18, 95% CI =−1.87; −0.89). Those who
were taking an antiretroviral were more likely to disclose their health status (Coef = 2.27, 95% CI = 0.6; 3.94). In addition,
a higher likelihood of being blamed/judged and shamed was associated with those who suffered from anxiety/depression
(Coef = 1.59, 95% CI = 0.24; 2.93 and Coef = 1.07, 95% CI = 0.36; 1.79, respectively).
Conclusions: MMT patients in these mountainous areas perceived high levels of stigma and discrimination which were
associated with mental health disorders, unemployment, and HIV infection. These findings highlighted the importance
of reducing drug use and HIV-related stigma against high-risk populations. Besides, psychosocial and familial supports,
as well as job referrals, also play crucial roles in terms of promoting quality of life among MMT patients.
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Background
Illicit drug misuse is a major global public health issue.
People who inject drugs (PWID) are more vulnerable to
various factors including the transmission of infectious
diseases [1]. In 2015, approximately 65% of all people living
with HIV were PWID [2]. A study carried out in northern
Vietnam also revealed significantly high prevalence of HIV,
hepatitis B virus (HBV), and hepatitis C virus (HCV)
among PWID (42.4, 80.9, and 74.1%, respectively) [3].
In response, Vietnam has shown vigorous efforts to
reduce the number of drug users as well as the incidence
of drug injection-related blood-borne diseases at both
national and international levels. The methadone main-
tenance treatment (MMT) program was first introduced
in Vietnam in 1996–1997, and by 2012, 61 MMT clinics
were available, providing treatment for 20 cities and
provinces across the country [4]. In 2006, harm reduc-
tion programs were implemented in 21 provinces with
various interventions including providing sterile syringes
and condoms, changing behavior, and counseling [5].
Vietnam has committed that, by 2020, 90% HIV-positive
people know their status, 90% of those diagnosed with
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HIV engage in antiretroviral therapy (ART), and 90% of
ART patients have durable viral suppression (“90-90-90”
targets) [6].
Harm reduction services have shown promising re-
sults. For instance, the previous literature revealed that
MMT could promote the quality of life, reduce the
frequency of illicit drug use [7], and minimize HIV-
related risk behaviors among illicit drug users [7–10].
Moreover, a needle exchange program (NEP) was effect-
ive in reducing blood-borne diseases [11].
However, these programs face formidable chal-
lenges partly due to high levels of stigma associated
with drug use [12]. These hamper the effectiveness
of drug treatment [13], limit the access to drug and
HIV/AIDS treatment [14], negatively affect health
status, and reduce treatment adherence [15, 16].
Therefore, to maximize the effectiveness of harm
reduction services, attention should be drawn to the
prevalence of stigma and discrimination experience
by drug users.
Stigma and discrimination against most-at-risk pop-
ulations have been studied in different health care
settings in Vietnam [17–19]; very few studies, how-
ever, have drawn much attention to rural and mountain-
ous areas where HIV has been increasingly prevalent
[20]. This study, therefore, aims to examine stigma
among MMT patients in mountainous areas in northern
Vietnam.
Methods
Study setting and sampling method
We conducted a cross-sectional study from May to
August 2016 in Tuyen Quang Province. Two MMTclinics
were involved in the study: one in Tuyen Quang City, a
third-grade urban area, and the other in Son Duong
District, a rural area. In fact, there are three MMT centers
in Tuyen Quang Province; however, we excluded one, Yen
Son District, because only nine patients have been treated
in this clinic due to its new establishment. Methadone
treatment in the two clinics is free of charge and funded
by the Australian government and the Royal Dutch
government. Apart from daily methadone treatment,
patients also receive health counseling from health staffs
working at these sites.
The sample included patients taking MMT in the
selected sites. The eligibility criteria included (1) taking or
initiating MMT in the selected sites, (2) presenting at the
clinics during the study period, (3) being 18 years old or
above, (4) having the capacity to answer the questionnaire,
and (5) agreeing to participate. We approached all patients
who were at the clinics and introduced the study. Those
who met the eligibility criteria were invited to enroll and
gave written informed consent if they agreed to participate
upon the understanding of the study’s purposes. Interviews
were administered in a private room. The patients did not
receive any compensation given that the medication was
provided free of charge. A convenient sample of 241
patients was recruited in the study. The response rate was
80–90% across the two sites.
Measurements and instruments
Face-to-face interviews were conducted by well-trained
interviewers including health staffs working at the Center
for Preventive Medicine, Tuyen Quang Province, and mas-
ter’s students of public health at Hanoi Medical University.
Socioeconomic characteristics
Socioeconomic characteristics included age, gender, educa-
tion level, marital status, employment status, ethnicity, reli-
gion, and household monthly income. Household monthly
spending was measured with two elements: recurring/
regular expenditure (namely food, clothes, rent, utility,
education) in the last 30 days and non-recurring/irregular
expenditure (e.g., health care, furniture, occasions, travel,
construction) in the last 12 months [21, 22].
Health status
Health-related quality of life (HRQOL) was measured
by using the EuroQol-five dimensions-five levels (EQ-
5D-5L) instrument. The instrument comprises five
domains: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression, with five levels of response:
no problems, slight problems, moderate problems, severe
problems, and extreme problems. To compute those
indexes, we employed the interim scoring for EQ-5D-5L
from the cross-walk value set of Thailand due to the
unavailability of the Vietnamese population’s preference
[23, 24]. The Vietnamese version of EQ-5D-5L was
translated and adopted as well as validated elsewhere
[24, 25]. Furthermore, we also asked the patients about
HIV status and acute and chronic illness.
Illicit drug use and rehabilitation
We collected the following information on the history of
drug abuse and current drug abuse.
Stigma/discrimination
We referred to the Substance Abuse Self-Stigma Scale
by Luoma et al. and measures of HIV-related stigma
[26]. In addition, we adapted the conceptual framework
by Parker and Aggleton to construct the measure of drug
addiction-related stigma among MMT patients [27]. We
then piloted the measures in drug users and people living
with HIV/AIDS. The final measure of stigma included five
dimensions: (1) blame/judgment, (2) shame, (3) discrimin-
ation in various settings (workplace, health care services,
family, and community), (4) disclosure of addiction or
health status (including HIV-positive if seropositive), and
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(5) others’ fear of HIV transmission among those patients
who self-reported being HIV-positive [28]. The respon-
dents were asked if they had experienced any of the above
types of stigma within the last month with the response
options ranging from 0 to 10 points, indicating “never
experience” and “always experience,” respectively. We
divided the score into three levels: 0 indicates “never
experience,” 1 to 9 suggests “experience,” and 10 indi-
cates “always experience.” The following are examples
of the items included:
1. Have you recently been blamed or criticized because
of your health status and drug use behaviors?
2. Do you currently feel shame because of your health
status and drug use behaviors?
3. Have you felt discriminated against or treated badly
by others? In which circumstances (workplace/all
health facilities/family/community/others)?
4. Have you ever disclosed your health status and drug
use behaviors with others? With whom did you share?
5. (For HIV positives) Has anyone expressed fear of
contracting HIV from casual contacts with you?
Statistical analysis
Data was analyzed by using STATA software version 12.0
(StataCorp LP, College Station, TX, USA). The Mann-
Whitney and chi-squared tests were employed to measure
the difference in levels of discrimination/stigma between
the two study sites. A p value <0.05 was considered sta-
tistically significant. In this study, a stepwise backward
selection strategy was applied along with multivariate
Tobit regression to have reduced models. This strategy
uses a threshold with the log-likelihood ratio test to
have predictors with p values <0.2 included.
Results
Table 1 provides the demographic information of the
respondents. In total, 241 patients participated in this
study; 167 patients were receiving MMT in Tuyen
Quang, and 74 patients were receiving MMT in Son
Duong. The most common ethnic group was Kinh
(92.2%). The mean age was 40.4 years (SD = 7.49). The
majority lived with a spouse or partner (62.3%). The
percentage of patients who were self-employed was
47.5% and only 6.4% was unemployed.
Table 2 illustrates the health status and risk behavior
among the respondents. There were a large proportion
of patients who were smokers (75.7%). A small percent-
age of patients reported health-related impairment:
mobility (14%), self-care (10.6%), usual activities (14.4%),
pain/discomfort (19.9%), and anxiety/depression (25.9%).
The average age at first drug use was 24.4 years (SD = 7.64)
and at first drug injection was 29.2 years (SD = 8.72). In
addition, the majority was negative for HIV (73.6%) and
25% of the respondents was positive. The percentage of
patients who were enrolled in ART was 22.8%. The number
of drug rehabilitation was 1.8 (SD = 1.08), and the duration
of MMT utilization was 15.3 months on average (SD =
8.66).
In Table 3, the proportion of stigma and discrimination
among MMT patients is shown. We found that most of
the enrolled patients experienced several types of discrim-
ination and stigma including blame/judgment (95.1%),
shame (95.1%), disclosure (71.4%), and the fear of HIV
transmission by others (74.1%). These percentages were
higher in Tuyen Quang than in Son Duong, except for the
category others’ fear of HIV (p < 0.05).
Table 4 indicates the various factors associated with
discrimination and stigma against drug users. Blame
was positively associated with those who attended high
school (Coef = 0.59; 95% CI = 0.03; 1.16). Those un-
employed were more likely to be discriminated (Coef =
−1.18, 95% CI = −1.87; −0.89). In addition, those who
received ARV treatment were associated with a lower
likelihood of being blamed and judged (Coef = −0.79,
95% CI = −1.4; −0.12), and they were more likely to
disclose their health status and drug use behavior
(Coef = 2.27, 95% CI = 0.6; 3.94). Lastly, those who
suffered from anxiety/depression were more likely to
Table 1 Demographics of respondents
Characteristics Number Percent
Education
<High school 111 47.0
≥High school 125 53.0
Marital status
Single 54 22.9













Tuyen Quang 167 69.3
Son Duong 74 30.7
Mean SD
Age 40.4 7.49
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be blamed/judged (Coef = 1.59, 95% CI = 0.24; 2.93)
and shamed (Coef = 1.07, 95% CI = 0.36; 1.79).
Discussion
This research enriched the existing literature on MMT-
related stigma and discrimination among those who live
in rural and mountainous areas in Vietnam by identify-
ing factors related to stigma and discrimination against
MMT patients, which have not been well documented
in previous studies. Although MMT has been known for
reducing risk behaviors and increasing the quality of life
among drug users [29–32], our results indicated that
stigma/discrimination significantly impacts MMT pa-
tients in northern Vietnam and feelings of stigma/
discrimination were especially high among unemployed
patients. In addition, those who were on antiretroviral
treatment were more likely to disclose their health status
and participants reporting anxiety and depression were
also more likely to report feeling blamed/judged and
shamed.
Stigma against drug users
Stigma and discrimination among drug users have
been previously reported in various health care ser-
vices [17, 19, 33]. In this study, the enrolled patients
experienced different kinds of stigma including blame/
judgment (95.1%), shame (95.1%), and others’ fear of
HIV transmission (74.1%), which is consistent with a
study by Jimeez et al. The study showed that 80% of
patients reported some level of felt stigma [34]. How-
ever, our results are higher than those of a previous
study in Hanoi, and Nam Dinh, which reported 17.2%
(blame/judgment), 19.9% (shame), and 17.1% (others’
fear of HIV transmission) [17]. These inconsistent
results can be explained by differences in the level of
awareness about and attitudes towards HIV/AIDS
among community members. A previous study by
Alemu et al. showed that the severity of stigma and
discrimination is influenced by the level of the
Table 2 Health status and risk behavior among respondents
Characteristics Number Percent
Concurrent drug use 31 13.4
Having a problem in mobility 33 14.0
Having a problem in self-care 25 10.6
Having a problem in usual activities 34 14.4
Having pain/discomfort 47 19.9









Age at first drug use 24.4 7.64
Months of drug use 168.4 83.82
Age at first drug injection 29.2 8.72
Number of drug rehabilitation 1.8 1.08
Duration of MMT (months) 15.3 8.66
BMI 21.2 2.33
EQ-5D-5L index 0.9 0.20
EQ VAS 81.8 15.27
Table 3 Discrimination/stigma among respondents
Characteristics Tuyen Quang Son Duong Total p value
n % n % n %
Blame/judge
No experience 2 1.2 10 13.5 12 5.0 <0.01
Experience 165 98.8 60 81.1 225 93.4
Always
experience
0 0.0 4 5.4 4 1.7
Shame
No experience 2 1.2 10 13.5 12 5.0 <0.01
Experience 163 97.6 61 82.4 224 93.0
Always
experience
2 1.2 3 4.1 5 2.1
Discrimination
No experience 7 4.2 7 9.5 14 5.8 0.22
Experience 159 95.2 66 89.2 225 93.4
Always
experience
1 0.6 1 1.4 2 0.8
Disclosure
No experience 43 25.8 26 35.1 69 28.6 <0.01
Experience 123 73.7 37 50.0 160 66.4
Always
experience
1 0.6 11 14.9 12 5.0
Others’ fear of HIV
No experience 6 50.0 0 0.0 6 26.1 0.01
Experience 6 50.0 9 81.8 15 65.2
Always
experience
0 0.0 2 18.2 2 8.7
Mean SD Mean SD Mean SD p value
Blame/judge 2.0 1.60 2.8 2.87 2.3 2.11 0.52
Shame 2.1 1.77 3.1 2.96 2.4 2.24 0.24
Discrimination 1.9 1.64 2.7 2.24 2.2 1.87 0.03
Disclosure 1.6 1.70 3.5 3.65 2.1 2.62 0.02
Others’ fear of HIV 2.2 2.48 2.9 3.56 2.5 3.00 0.38
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community’s awareness about HIV/AIDS [35]. Those
who live in cities are more likely to be well aware of
HIV/AIDS than those who live in rural areas. All the
participants in our study live in rural areas, which may
help to explain the higher proportion of stigma/
discrimination against drug users than that of a study
in Vietnam’s capital, Hanoi, and Nam Dinh Province.
Discrimination has been shown to adversely affect the
health of illicit drug users. Some previous studies
suggested that discrimination and alienation are associ-
ated with poor mental and physical health [36, 37]. Our
finding remarkably contributed to the literature as we
found that those who suffered from mental health
problems were more likely to report some forms of
stigma and discrimination as well. Further research
should be performed to understand the mutual relation-
ship between stigma/discrimination and health among
marginalized populations.
Factors related to stigma against drug users
Our study found that those who were unemployed were
more likely to report self-stigmatization, which is consistent
with the aforementioned study in Hanoi and Nam Dinh
Province. The relationship between stigma/discrimination
and employment is a complex process; stigma/discrimin-
ation can act as a barrier to work, and being unemployed
may fuel stigma against drug users. A review of the
literature by Sutton et al. identified that one of the main
barriers to work among drug users was the problem of
stigma [38]. In Vietnam, stigma and discrimination against
people living with HIV/AIDS are a pressing issue due to
the propaganda associating HIV with the social evils of sex
work and drug use [18, 39–41]; these barriers may prevent
them from obtaining employment [42]. Our study was
carried out in rural areas, where stigma against drug users
is far worse, which may result in the significantly inverse
correlation between stigma and employment.
It was also noteworthy to find that those who were on
antiretroviral treatment were more likely to report self-
disclosure. Evidence suggested that stigma and discrimin-
ation against people living with HIV in the community
and health care settings persistently hinder the utilization
of HIV-related treatment services [18, 41]; this helps to
explain why those who were on antiretroviral treatment
Table 4 Factor associated with discrimination and stigma among respondents
Characteristics Blame/judge Shame Discrimination Disclosure
Coef 95% CI Coef 95% CI Coef 95% CI Coef 95% CI
Education (vs <high school)
High school 0.59** 0.03; 1.16 0.58* −0.04; 1.20 −0.78** −1.48; −0.08
>High school −1.46* −3.01; 0.1
Employment (vs unemployment)
Worker/farmer −1.18*** −1.87; −0.49
HIV test results (vs negative)
Positive 0.69* −0.02; 1.40 1.36 −0.27; 2.99
Marital (vs single)
Divorced/widow −0.53 −1.21; 0.15
Income quintile (vs poorest)
Middle −0.73** −1.41; −0.04
Richest −0.90** −1.68; −0.11 −0.77** −1.41; −0.13
Number of drug rehabilitation (vs none)
1 time −0.46 −1.07; 0.14 −0.47* −0.99; 0.04
>2 times 0.55 −0.19; 1.28
Receiving ART (yes vs no) −0.79** −1.45; −0.12 2.27*** 0.6; 3.94
Location (Son Duong vs Tuyen Quang) 0.78** 0.14; 1.42 1.01*** 0.31; 1.71 1.40*** 0.81; 2.00 2.16*** 1.38; 2.93
Having a problem in usual activities (yes vs no) 1.68** 0.29; 3.07 1.69*** 0.53; 2.86 1.19** 0.02; 2.36
Pain/discomfort (yes vs no) 1.11 −0.23; 2.46
Anxiety/depression (yes vs no) 1.59** 0.24; 2.93 1.07*** 0.36; 1.79 1.49** 0.36; 2.63 0.77 −0.43; 1.97
Concurrent drug use (yes vs no) 0.79 −0.17; 1.75
EQ-5D-5L index 3.47* −0.36; 7.3 2.69* −0.52; 5.90
Age −0.05** −0.1; −0.01
***p < 0.01, **p < 0.05, *p < 0.1
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tended to disclose their health status as they may feel less
self-stigmatized. A study by Duong et al. suggested that
self-disclosure may help those high-risk populations to
increase access to HIV-related care [42].
Implications
Several implications can be drawn from this study. First,
as stigma was higher in unemployed MMT patients, it is
suggested that more attention should be paid to the
lower socioeconomic methadone group. This can be
done by moving MMT clinics to commune health cen-
ters so that patients can easily access drug treatment
without long-hour traveling, thereby saving a great deal
of time and boosting chances of employment. Besides,
job opportunities should also be considered by relevant
stakeholders. Second, as MMT patients in mountainous
areas perceived an unexpectedly high level of stigma and
discrimination, mass community-based behavioral change
campaigns should be prioritized in order to raise know-
ledge and awareness about HIV/AIDS. In fact, many
Vietnamese hesitate to make contact with HIV-positive
people due to the misconception about how HIV is
transmitted; a vast majority of people believe that HIV
can be easily transmitted by mere touching [43]. Finally,
our finding indicated that stigma and discrimination are in
an intimate relationship with impaired physical and mental
health; therefore, a comprehensive approach combining
social, family, and health care supports should be consid-
ered to alleviate drug addiction-related stigma, thereby
promoting the overall health status of methadone patients.
Limitations
Several limitations of this study should be taken into
consideration. First, our data was cross-sectional;
therefore, we could only observe stigma and discrimin-
ation prevalence among methadone patients at one point
in time. The outcomes of interest, namely stigma and
discrimination, were evaluated in the last 30 days, while
the health-related quality of life was measured using EQ-
5D-5L during presentation at the clinics. This may lead to
a temporal relationship between the quality of life and
stigma/discrimination. Therefore, a longitudinal study will
provide a greater insight into how multiple factors can
influence stigma and discrimination against MMT pa-
tients. Second, recall bias may occur due to self-reported
information, which can lead to data bias. Finally, we chose
the convenient sampling technique in our study. This may
increase the risk of data bias, which clouds the study
results. In addition, this sample included only those
patients who had engaged in or accessed MMT services
while lacked other drug users without treatment. Thus,
these findings are not generalizable to injection drug users
not engaged in methadone treatment or non-opioid-
injecting participants. Ideally, accessing MMT services
may reduce stigma and discrimination by counseling or
motivational interviewing, as well as the familial supports
for the patients as required by the program. As a result,
this might lead to an underestimation of the out-
comes of interest.
Conclusions
In conclusion, our study emphasized that MMT patients
in mountainous areas in northern Vietnam experienced
significantly high levels of stigma and discrimination.
The findings suggested the need for raising awareness
among populations about HIV/AIDS to reduce stigma.
Moreover, the study also highlighted the importance of
social supports, as well as job referrals, in terms of dimin-
ishing self-stigmatization and promoting quality of life
among MMT patients.
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